Literature DB >> 19434314

Immunohistochemical expression and significance of epidermal growth factor receptor (EGFR) in breast cancer.

Adriana Meche1, Anca Maria Cîmpean, M Raica.   

Abstract

Breast cancer is a heterogeneous disease that includes several molecular types, characterized by the expression profile of sex hormone receptors, HER2 protein, cytokeratin 5, p53, and Bcl-2. EGFR is an additional marker predominantly expressed by basal-like carcinoma, but its significance in the other types is not completely understood. The aim of this study was to analyze the immunohistochemical expression of EGFR and its relationships with other factors of prognosis. There were investigated benign lesions and 84 cases with invasive breast carcinoma that were submitted first to the molecular classification. Next, we performed the staining for EGFR and two patterns of the final product of reaction were described. EGFR expression was found in 41.66% of the cases with basal-like carcinoma, in 50% of the cases with luminal B carcinoma, and in 21.42% of the cases with HER2 overexpression. A significant correlation was found between EGFR expression and degree of differentiation and distant metastasis. No significant correlation was found with the lymph node status, excepting for the basal-like carcinoma in which an inverse correlation was noticed. Our results suggest that EGFR expression by tumor cells of the breast cancer defines a specific subset of tumors with poor prognosis and potential resistance to the adjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19434314

Source DB:  PubMed          Journal:  Rom J Morphol Embryol        ISSN: 1220-0522            Impact factor:   1.033


  8 in total

1.  PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.

Authors:  Michaela J Higgins; Julia A Beaver; Hong Yuen Wong; John P Gustin; Josh D Lauring; Joseph P Garay; Hiroyuki Konishi; Morassa Mohseni; Grace M Wang; Justin Cidado; Danijela Jelovac; David P Cosgrove; Akina Tamaki; Abde M Abukhdeir; Ben Ho Park
Journal:  Cancer Biol Ther       Date:  2011-02-01       Impact factor: 4.742

2.  Gene expression-based classification of non-small cell lung carcinomas and survival prediction.

Authors:  Jun Hou; Joachim Aerts; Bianca den Hamer; Wilfred van Ijcken; Michael den Bakker; Peter Riegman; Cor van der Leest; Peter van der Spek; John A Foekens; Henk C Hoogsteden; Frank Grosveld; Sjaak Philipsen
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

Review 3.  Characteristics of triple-negative breast cancer.

Authors:  Tim C de Ruijter; Jürgen Veeck; Joep P J de Hoon; Manon van Engeland; Vivianne C Tjan-Heijnen
Journal:  J Cancer Res Clin Oncol       Date:  2010-11-11       Impact factor: 4.553

4.  In Silico Design and Analysis of TGFαL3-SEB Fusion Protein as "a New Antitumor Agent" Candidate by Ligand-Targeted Superantigens Technique.

Authors:  Abbas Ali Imani-Fooladi; Forough Yousefi; Seyed Fazloallah Mousavi; Jafar Amani
Journal:  Iran J Cancer Prev       Date:  2014

5.  EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.

Authors:  James P De Andrade; Jung M Park; Vivian W Gu; George W Woodfield; Mikhail V Kulak; Allison W Lorenzen; Vincent T Wu; Sarah E Van Dorin; Philip M Spanheimer; Ronald J Weigel
Journal:  Mol Cancer Ther       Date:  2016-02-01       Impact factor: 6.261

6.  Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers.

Authors:  Giorgio Secreto; Elisabetta Venturelli; Elisabetta Meneghini; Maria Luisa Carcangiu; Biagio Paolini; Roberto Agresti; Cristina Pellitteri; Franco Berrino; Massimo Gion; Patrizia Cogliati; Giuseppina Saragò; Andrea Micheli
Journal:  BMC Cancer       Date:  2012-12-14       Impact factor: 4.430

7.  Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas.

Authors:  Arathi A Changavi; Arundhathi Shashikala; Ashwini S Ramji
Journal:  J Lab Physicians       Date:  2015 Jul-Dec

8.  Erlotinib: An enhancer of radiation therapy in nasopharyngeal carcinoma.

Authors:  Huan-Huan Zhang; Tai-Ze Yuan; Jian Li; Yin Liang; Lai-Ji Huang; Jia-Cai Ye; Rong-Hui Zheng; Guo-Feng Xie; Xiu-Ping Zhang
Journal:  Exp Ther Med       Date:  2013-08-02       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.